Publications by authors named "Christine Getter"
Introduction: Three (18)F-labeled radiopharmaceuticals have been Food and Drug Administration-approved for the identification of cortical amyloidosis in clinical settings. Although there has been strong debate among professionals as to the ethical and social consequences of disclosing such information, increasing numbers of participants are being recruited into secondary prevention trials for which they are likely to, and/or desire to, receive their positron emission tomography (PET) imaging results.
Methods: Healthy older adults (n = 63, mean age = 62 years) enrolled in a preclinical Alzheimer's disease (AD) biomarkers trial, and 11 requested disclosure of PET amyloid imaging results to their treating neurologist, per institutional review board-approved study protocol.
Background: Abnormal β-amyloid (Aβ) is associated with deleterious changes in central acetylcholinergic tone in the very early stages of Alzheimer's disease (AD), which may be unmasked by a cholinergic antagonist. We aimed to establish an optimal "microdose" of scopolamine for the development of a "cognitive stress test."
Methods: Healthy older adults (n = 26, aged 55-75 years) with two risk factors for AD, but with low cortical Aβ burden, completed the Groton Maze Learning Test (GMLT) at baseline and then received scopolamine (0.
Purpose: To assess the domain structure and to evaluate the psychometric properties of the Cancer Therapy Satisfaction Questionnaire (CTSQ) and the relation between the CTSQ and health-related quality of life (HRQOL).
Methods: Three hundred sixty-one individuals with breast, colorectal, lung cancer, or melanoma who had received in the last 6 months or were currently receiving more than one cycle of chemo, biological, or hormonal therapy completed the 21-item CTSQ, with a random subsample of 88 patients completing it again 1 week later. Participants also completed quality of life, treatment satisfaction, and other self-reported questions on each occasion.